This instance provides for the evidence that PDGFR-inhibition by tyrosine kinase inhibitors (TKIs) appear to be beneficial in chronic airway disease, e.g. idiopathic pulmonary fibrosis (IPF) [3–5] or asthma [6, 7]. The gene discussed is PDGFRB; the disease is pulmonary fibrosis.